Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > This is why i love this board
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Jan 24, 2023 8:24am
91 Views
Post# 35241759

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:This is why i love this board

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:This is why i love this board Well, narmac, I've pretty much exhausted what I have to say about it all.

The question about whether one believes or not that xB3 works is legitimate only in the sense that one has the right to believe what one wants. The world is round but one can believe it flat. xB3 so far has shown that it works, but one can believe it does not.

Shareholders have just over a week to decide whether they'll give DrDR a free hand to do what she can or wants with Bioasis. My worry is that she has given up and may arrange the outright sale of the company to a private entity for 10¢ or maybe a little more and that out of weariness and with no time left and no other choices, shareholders will approve it. DrDR could then join the buyers and go on to make the fortune she knows is possible, if not likely. 

That would put Bioasis, its shareholders and this forum, finally, out of their collective misery.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities